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ABSTRACT
We report the occurrence of serious reactions after treatment with oral ivermectin in two patients with Mansonella 
ozzardi infections. Both had systemic and respiratory symptoms and recovered without sequelae. Follow-up revealed 
clearance of microfilaremia in both cases, with relapse in one of them. These reactions are well described in the treat-
ment of other filarial infections, but  have not yet been reported in the treatment of M. ozzardi. We are now reporting 
the first such known reactions with this helminthiasis.
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RESUMEN
Efectos clínicos adversos relacionados con ivermectina en pacientes tratados por infecciones con Manso-
nella ozzarddi. Se informa la aparición de reacciones adversas graves con el tratamiento con ivermectina oral en 
dos pacientes con infección por Mansonella ozzardi. Ambos presentaron síntomas respiratorios y sistémicos y se 
recuperaron sin secuelas. El seguimiento mostró ausencia de microfilaremia en ambos casos, con recidiva en uno 
de ellos. Estas reacciones, bien conocidas durante el tratamiento de otras filariosis, se describen por primera vez 
con esta helmintiasis.
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The filarial parasite Mansonella ozzardi causes infec-
tions in the tropical regions of Central and South America 
and the Caribbean. In Argentina, Biglieri and Araoz de-
scribed the first cases in the Province of Tucumán in 
1914 (1), at a time when no other human filarial infections 
were identified in this area. The Yungas, an ecological 
area characterized by tropical rainforest spreading from 
northwestern Argentina to southern Bolivia is endemic for 
M. ozzardi. Culicoides lahillei has been postulated as the 
principal vector in the area, with transmission occurring 
primarily during the wet season (9). A prevalence of M. 
ozzardi infection of 20.7% was reported (10) in El Oculto, 
a village with 80 inhabitants in the Yungas, in the Province 
of Salta (altitude 700 meters), Argentina. 
Currently, ivermectin is the first-line drug for the treat-
ment of filarial infections due to its efficacy and safety; over 
400 million doses have been prescribed with excellent 
results and only a few cases with severe complications 
have been reported in the treatment of loiasis and oncho-
cerciasis (2, 3). The side effects associated with treating 
patients infected with Loa loa are believed to be due to an 
exaggerated inflammatory response to the dying parasites 
(3). There is little experience in the treatment of infections 
due to M. ozzardi, which appears to be susceptible to 
ivermectin but resistant to diethylcarbamazine (7). 
This report comments on two cases of serious adverse 
events related to ivermectin in the treatment of infections 
due to M. ozzardi in the department of Oran, Province of 
Salta, Argentina.
In the area of El Oculto in Salta (Figure 1), 10 symp-
tomatic patients over a 15 year period agreed to the 
off-label use of a single dose of ivermectin (12 mg orally) 
for the treatment of M. ozzardi infection. All the patients 
were permanent residents of the community suffering 
from musculoskeletal symptoms. Diagnosis was made 
by the Knott’s concentration test in blood obtained from 
venopuncture (5). Two patients developed serious adverse 
events following ivermectin (Securo, Valeant Argentina, 6 
mg tablets) administration.
Case 1 was a 70 -year-old female with no remarkable 
medical history who presented with bilateral non-inflam-
matory edema of her knees and shoulder pain. She had 
lived her entire life in the Yungas and settled in El Oculto 
in 1970. Her peripheral blood smear stained with the 
Knott´s technique (Figure 2) revealed microfilaremia 
caused by M. ozzardi, with mild to moderate micro-
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filaremia density. She was treated with 190 µg/kg of 
ivermectin. Within 12 hours of ivermectin administration, 
she started complaining of severe malaise, chills, fever 
and moderate dyspnea, which kept her bedridden. Her 
symptoms improved after 3 days and recovered without 
sequelae. The patient used non-concomitant medi-
cal or herbal therapies and recovered without further 
treatment. Blood smear examination with the Knott’s 
technique revealed no microfilaremia 2 weeks after 
treatment, but a relapse was confirmed in a follow-up 
evaluation 5 years later. The patient was admitted to 
the local hospital and treated under medical supervision 
with ivermectin 200 µg/kg without any side effects. A 
follow-up evaluation 3 months after treatment revealed 
no microfilaremia.
Case 2 was a 68-year-old male without remarkable 
medical history, who presented with bilateral knee pain 
and generalized myalgias, and was found to have mild 
to moderate density of M. ozzardi microfilaria using the 
Knott’s technique in his peripheral blood smear. He had 
lived in El Oculto since 1972. Six hours after receiving 158 
µg/kg of ivermectin he began to have chills and malaise, 
followed by an episode of acute shortness of breath. He 
was assisted by his neighbors and recovered without se-
quelae after 2 days. He was not taking any concomitant 
therapy, but used local herbal infusions during his recov-
ery. A follow-up examination revealed no microfilaremia 
in a blood smear 3 weeks after treatment.
Both cases were informed to the medical team in a 
follow-up visit to the village; three other patients who had 
lived in the endemic area for 25, 20 and 10 years, who 
were treated with ivermectin for M. ozzardi infections dur-
ing the same period did not report any adverse events; 
they were of similar age and also had mild-moderate 
infection density in peripheral blood. Follow-up testing 
for microfilaremia performed between 30 and 60 days 
after therapy was negative in 2 of the 3 patients without 
adverse events; no follow-up smears were performed in 
the remaining patient.
We report the occurrence of serious adverse events in 
patients with infections due to M. ozzardi that resemble 
excessive forms of the expected Mazzotti’s reaction 
seen upon treatment of other filarial infections; the lack 
of dermatologic findings in these cases might be related 
to the absence of the dermal localization that has been 
described for M. ozzardi (8). Due to the remoteness of 
Figure 2. Mansonella ozzardi microfilaria seen in a Giemsa stained blood smear of patient 
case 1 prepared with the Knott’s technique. 1,000 x magnification under immersion oil.
Figure 1. Geographic location of El Oculto in the Province of Salta, Argentina.
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the patient’s village, their reactions resolved without any 
medical attention or intervention. 
In a bibliographic review of the published literature, the 
only report of events similar to our observations appears 
in the first report on the use of ivermectin against M. oz-
zardi, where a traveler with asthma and childhood allergies 
developed urticaria, fever and wheezing 12 hours after 
taking ivermectin. Her symptoms were rapidly controlled 
with epinephrine (7). In a clinical trial of ivermectin against 
M. ozzardi infections in Trinidad, 15% of the patients had 
severe reactions mostly consisting of fever, arthralgias 
and headache (4). Infection intensity, which is positively 
correlated with the severity of Mazzotti’s reaction and other 
adverse events related to the treatment of filarial infec-
tions (6), could not be verified in our cases. In our group 
of patients, despite no statistically significant differences, 
patients with symptoms were those who had lived longer 
in the endemic area, which could be a surrogate marker 
for intensity of infection.
In summary, serious adverse events previously ob-
served in the treatment of filarial infections could pos-
sibly be expected with M. ozzardi infections. Based on 
this report, and until further studies can be conducted, 
acute adverse events could be expected in patients with 
M. ozzardi and the convenience of its treatment weighed 
against the risk of adverse events. The availability of 
medical resources to treat adverse events (corticosteroids 
and epinephrine) and the case-by-case decision on the 
convenience of treatment appear to be required issues in 
the management of these patients. 
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